Preclinical Profiling and Safety Studies of ABT-769: A Compound with Potential for Broad-spectrum Antiepileptic Activity
Article first published online: 1 SEP 2005
Volume 46, Issue 9, pages 1349–1361, September 2005
How to Cite
Giardina, W. J., Dart, M. J., Harris, R. R., Bitner, R. S., Radek, R. J., Fox, G. B., Chemburkar, S. R., Marsh, K. C., Waring, J. F., Hui, J. Y., Chen, J., Curzon, P., Grayson, G. K., Komater, V. A., Ku, Y., Lockwood, M., Miner, H. M., Nikkel, A. L., Pan, J. B., Pu, Y.-M., Wang, L., Bennani, Y., Durmuller, N., Jolly, R., Roux, S., Sullivan, J. P. and Decker, M. W. (2005), Preclinical Profiling and Safety Studies of ABT-769: A Compound with Potential for Broad-spectrum Antiepileptic Activity. Epilepsia, 46: 1349–1361. doi: 10.1111/j.1528-1167.2005.02905.x
- Issue published online: 1 SEP 2005
- Article first published online: 1 SEP 2005
- Accepted April 24, 2005.
- Valproic acid;
- Anticonvulsant drugs;
- Animal seizure models;
- Maximal electroshock;
- Kindled amygdala seizures;
- Absence seizures
Summary: Purpose: The objective of this study was to characterize the antiseizure and safety profiles of ABT-769 [(R)-N-(2 amino-2-oxoethyl)spiro[2,5]octane-1-carboxamide].
Methods: ABT-769 was tested for protection against maximal electroshock and pentylenetetrazol-induced seizures in the mouse and for suppression of electrically kindled amygdala seizures and spontaneous absence-like seizures in the rat. The central nervous system safety profile was evaluated by using tests of motor coordination and inhibitory avoidance. The potential for liver toxicity was assessed in vitro by using a mitochondrial fatty acid β-oxidation assay. Teratogenic potential was assessed in the mouse.
Results: ABT-769 blocked maximal electroshock, subcutaneous pentylenetetrazol and intravenous pentylenetetrazol–induced seizures with median effective dose (ED50) values of 0.25, 0.38, and 0.11 mmol/kg, p.o., respectively. No tolerance was evident in the intravenous pentylenetetrazol test after twice-daily dosing of ABT-769 (0.3 mmol/kg, p.o.) for 4 days. ABT-769 blocked absence-like spike–wave discharge (ED50, 0.15 mmol/kg, p.o.) and shortened the cortical and amygdala afterdischarge duration of kindled seizures (1 and 3 mmol/kg, p.o.). The protective indices (ED50 rotorod impairment/ED50 seizure protection) were 4.8, 3.2, and 10.9 in the maximal electroshock, subcutaneous pentylenetetrazol and intravenous pentylenetetrazol seizure tests, respectively. ABT-769 did not affect inhibitory avoidance performance (0.1–1 mmol/kg, p.o.). ABT-769 did not affect mitochondrial fatty acid β-oxidation or induce neural tube defects.
Conclusions: ABT-769 is an efficacious antiseizure agent in animal models of convulsive and nonconvulsive epilepsy and has a favorable safety profile. ABT-769 has a broad-spectrum profile like that of valproic acid. Its profile is clearly different from those of carbamazepine, phenytoin, lamotrigine, topiramate, vigabatrin, and tiagabine.